We found that AKAP6-rs2239647 significantly affected the PFS of patients with high-level glioma (WHO grade III–IV), and patients with CA genotype had a better prognosis (PFS: log-rank p = 0.045, HR = 1.67, p = 0.034). Here, AKAP6 is linked to glioma.